Article

Breast Cancer Incidence Among Black Women May Vary Substantially by Birthplace

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

There is substantial variation in the prevalence of triple-negative breast cancer among black women by birthplace, affirming that incidence of the disease among black women is not generalizable, according to a new study published in Cancer.

Triple-negative breast cancer that is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor, is approximately twice as common among black women than white women in the United States. However, black populations in the United States are diverse and incidence rates may differ by birthplace, the researchers noted.

For the study, the authors examined the prevalence of triple-negative and hormone receptor-negative breast cancer among black women in the National Program of Cancer Registries and US Cancer Statistics. Overall, the authors identified 65,211 non-Hispanic black women who were diagnosed with invasive breast cancer from 2010 to 2015. Varying birthplaces in the United States, East Africa, West Africa, or the Caribbean were reported.

Compared with US-born black women, the prevalence rate ratio of triple-negative breast cancer was 8% lower among Western-African-born women, 13% lower among Caribbean-born women, and 46% lower among Eastern-African-born black women, according to the study.

Examining nativity-related differences among black women can help foster a better understanding of the etiologic heterogeneity of breast cancer, the researchers noted.

“It is not clear what risk factors conferred by birthplace are associated with subtype prevalence,” lead study author Hyuna Sun, PhD, of the American Cancer Society, said in a press release. “However, the similarity in breast cancer subtype prevalence between US-born and Western-African-born blacks, contrasted against the differences with Eastern-African-born blacks, may in part reflect shared ancestry-related risk factors.”

Despite a previous understanding of the higher proportional burden of breast cancer among black women, the researchers suggested that this notion is not reflective of the diverse black population. Furthermore, a more complete collection of birthplace information in cancer registries can help improve the specificity of understanding potential ancestry-related risk factors.

“These findings underscore the importance of considering geographic origin in studies characterizing breast cancer among women of African descent in the United States and elsewhere,” the researchers concluded in the study.

References

Sung H, DeSantis CE, Fedewa SA, et al. Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. Cancer. 2019. Doi: https://doi.org/10.1002/cncr.32293

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards